Clinical trials for Prostate cancer

169 currently recruiting clinical trials
Phase 2 Prostate cancer #NCT07287150 #2025-521327-67-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
4 recruiting sites
Hoffmann-La Roche
Phase 2 Prostate cancer #NCT06582628 #2023-510536-37-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Hormone therapy
5 recruiting sites
Fundacion Oncosur
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT02029001 #2012-004510-34
Cohorte Olaparib
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM BRCA 1/2 PALB2 Other mutation
Required number of previous lines of therapy
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Skin cancer #NCT02029001 #2012-004510-34
Cohorte Durvalumab + Tremelimumab
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Bispecific T-cell engager antibodies
7 recruiting sites
Centre Léon Bérard
Phase 2 Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT07016230 #2024-515847-47-00
Cohorte 2
Required histologic types
Neuroendocrine tumor/carcinoma other than SCLC Stomach Thyroid cancer
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors #NCT07359820 #2025-523923-22-00
Required histologic sub types
Hepatocellular carcinoma Hepatocholangiocarcinoma Ampullary carcinoma
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Elevar Therapeutics
Phase 2 Breast cancer Lung cancer Prostate cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07209111 #2025-521737-91-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT06022289
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
FGFR
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Tianjin Medical University Second Hospital
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT05503797 #2024-513578-23-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
HRAS KRAS G12C KRAS non G12C NRAS
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT05503797 #2024-513578-23-00
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
HRAS KRAS G12C KRAS non G12C NRAS
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics